2m 2m 2m 2m 2m 2m 2m
GYRE THERAP (GYRE)
NASDAQ
$5.86-$0.005 (-0.09%)
Price as of Oct 22, 2026 7:30 PM EDT- $625.6MMarket Cap
- -25.22%1-Year Change
- BiotechnologyIndustry
GYRE THERAP (GYRE)
$5.86-$0.005 (-0.09%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 116.6M +10.24% | 105.8M -6.78% | 113.5M +7,017.31% | 1.6M -78.28% | |
Cost of Revenue | 5.4M +39.44% | 3.9M -16.22% | 4.6M +480.95% | 798,000 -89.19% | |
Gross Profit | 111.2M +9.13% | 101.9M -6.38% | 108.8M +13,570.10% | 796,000 +1,995.24% | |
Sales and Marketing Expense | 65.2M +13.33% | 57.5M -5.96% | 61.2M N/A | N/A N/A | |
Research and Development Expense | -13.7M +13.92% | -12.0M -12.74% | -13.8M -71.54% | -48.4M -29.70% | |
Depreciation and Amortization Expense | 2.5M +60.17% | 1.5M +44.23% | 1.1M +366.96% | 230,000 -20.69% | |
Total Operating Expenses | 105.1M +17.31% | 89.6M -50.41% | 180.7M +1,821.11% | 9.4M -90.12% | |
Operating Profit | 11.5M -28.93% | 16.2M +124.04% | -67.2M +680.75% | -8.6M -90.20% | |
Interest Income | N/A N/A | N/A N/A | 1.1M N/A | N/A N/A | |
Interest Expense | N/A N/A | -6,000 N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 +100.00% | -6,000 -100.56% | 1.1M N/A | 0 N/A | |
Total Nonoperating Income and Expense | -1.5M -9.28% | -1.7M -258.91% | 1.0M +1,438.46% | -78,000 -10.34% | |
Income before Taxes | 14.4M -37.82% | 23.2M +130.17% | -77.0M +874.98% | -7.9M -91.02% | |
Income Taxes | 4.6M -14.36% | 5.3M -37.52% | 8.5M +2,346.84% | 348,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 5.0M -58.40% | 12.1M +113.00% | -92.9M +1,027.55% | -8.2M -90.63% | |
Net Income from Continuing Operations Applicable to Common | 5.0M -58.40% | 12.1M +113.00% | -92.9M +1,077.26% | -7.9M -91.02% | |
Basic EPS and Net Income | 0.06 -57.14% | 0.14 +109.93% | -1.41 +442.31% | -0.26 -90.94% | |
Diluted EPS and Net Income | 0.02 -60.00% | 0.05 +103.55% | -1.41 +442.31% | -0.26 -90.94% | |
Basic Weighted Average Shares | 89.3M +4.99% | 85.1M +29.26% | 65.8M +108.69% | 31.5M +2.95% | |
Diluted Weighted Average Shares | 103.2M +0.87% | 102.3M +55.39% | 65.8M +108.69% | 31.5M +2.95% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 37.1M +213.81% | 11.8M -64.75% | 33.5M +54.66% | 21.7M -51.14% | |
Short-Term Investments | 15.4M +3.34% | 14.9M N/A | N/A N/A | 2.5M 0.00% | |
Cash and Cash Equivalents and Short-Term Investments | 52.4M +96.56% | 26.7M -20.41% | 33.5M +38.64% | 24.2M -48.41% | |
Total Current Assets | 102.4M +58.01% | 64.8M +13.22% | 57.2M +102.87% | 28.2M -45.21% | |
Accumulated Depreciation | 7.6M +35.31% | 5.6M +31.28% | 4.3M N/A | N/A N/A | |
Property and Plant and Equipment and Net | 23.6M -1.18% | 23.9M +2.54% | 23.3M +582,100.00% | 4,000 -99.59% | |
Total Long-Term Assets | 2.5M -17.76% | 3.0M +204.52% | 995,000 +492.26% | 168,000 -64.41% | |
Total Assets | 166.1M +32.48% | 125.4M +7.61% | 116.5M +309.71% | 28.4M -48.90% | |
Income Taxes Payable | 2.9M +3.85% | 2.8M -43.98% | 5.1M N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 18.3M -6.30% | 19.5M -2.65% | 20.0M +19.16% | 16.8M +18.77% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.4M +20,585.71% | 7,000 -85.71% | 49,000 -87.99% | 408,000 0.00% | |
Total Liabilities | 23.9M -11.68% | 27.0M -29.06% | 38.1M +126.25% | 16.8M +15.45% | |
Retained Earnings | -68.4M -6.84% | -73.5M -14.13% | -85.5M -79.18% | -410.9M +2.05% | |
Total Stockholders Equity | 106.0M +67.46% | 63.3M +500.04% | -15.8M -27.02% | -21.7M -152.79% | |
Total Shares Outstanding | 91.3M +5.80% | 86.3M +12.68% | 76.6M +102.87% | 37.8M +20.21% | |
Cash Flow | |||||
Cash from Operating Activities | 1.0M +127.74% | -3.6M -114.06% | 25.9M +178.23% | -33.1M -60.48% | |
Capital Expenditures | 1.2M -48.60% | 2.3M -72.82% | 8.5M +915.14% | 839,000 N/A | |
Cash from Investing Activities | -474,000 -97.62% | -19.9M +0.63% | -19.8M -135.65% | 55.4M +15.02% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | 45.0M N/A | |
Cash from Financing Activities | 24.4M +1,059.75% | 2.1M -15.92% | 2.5M +105.55% | -45.0M -190.83% | |
Financials Ratio | |||||
Gross Margin | 95.35% -1.01% | 96.33% +0.43% | 95.91% +92.07% | 49.94% +8,824.20% | |
Operating Margin | 9.85% -35.53% | 15.28% +125.79% | -59.26% -89.03% | -540.21% -54.90% | |
Return on Assets | 3.45% -65.48% | 9.99% +107.79% | -128.20% +554.10% | -19.60% -83.23% | |
Return on Equity | 5.94% -88.33% | 50.89% -89.73% | 495.42% +683.06% | -84.97% -43.40% | |
Revenue Growth | 10.24% +251.03% | -6.78% -100.10% | 7,017.31% +9,064.66% | -78.28% +20.48% | |
Current Ratio | 5.60 +68.64% | 3.32 +16.30% | 2.85 +70.25% | 1.68 -53.87% | |
Cash Ratio | 2.03 +234.91% | 0.61 -63.79% | 1.67 +29.79% | 1.29 -58.87% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow